Summary On July 1, 2014, the United States Food and Drug Administration granted
'breakthrough therapy'designation to CTL 019, the anti‐CD 19 chimeric antigen receptor T …

Improved outcomes for patients with cancer hinge on the development of new targeted
therapies with acceptable short-term and long-term toxicity. Progress in basic, preclinical …

Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is highly promising but requires
robust T-cell expansion and engraftment. A T-cell defect in chronic lymphocytic leukemia …

The success of chimeric antigen receptor (CAR)–mediated immunotherapy in acute
lymphoblastic leukemia (ALL) highlights the potential of T-cell therapies with directed …

We designed a lentiviral vector expressing a chimeric antigen receptor with specificity for the
B-cell antigen CD19, coupled with CD137 (a costimulatory receptor in T cells [4-1BB]) and …

Purpose: Chimeric antigen receptor–modified T cells (CAR-T) have demonstrated
encouraging results in early-phase clinical trials. Successful adaptation of CAR-T …

Increasing immune responses with immunostimulatory monoclonal antibodies (mAbs)
directed to immune-receptor molecules is a new and exciting strategy in cancer therapy …

Adoptive immunotherapy, or the infusion of lymphocytes, is a promising approach for the
treatment of cancer and certain chronic viral infections. The application of the principles of …

Adoptive immunotherapies based on the transfer of functional immune cells hold great
promise in treating a wide range of malignant diseases, especially cancers, autoimmune …

Purpose To evaluate the role of donor lymphocyte infusion (DLI) in the treatment of relapsed
acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation …